Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: A randomised placebo controlled trial

BMJ

Volumn 342, Issue 7787, 2011, Pages 36-

  Galan, Pilar ^a   Kesse Guyot, Emmanuelle ^a   Czernichow, Sébastien ^a,b   Briancon, Serge ^c   Blacher, Jacques ^a,d   Hercberg, Serge ^a,b  

^a UNIVERSITÉ PARIS 13   (France)

^b AVICENNE HOSPITAL   (France)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 METHYLTETRAHYDROFOLIC ACID; CYANOCOBALAMIN; DOCOSAHEXAENOIC ACID; HOMOCYSTEINE; ICOSAPENTAENOIC ACID; PLACEBO; PYRIDOXINE;

ADULT; ARTICLE; BLOOD LEVEL; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOUBLE BLIND PROCEDURE; FEMALE; HAZARD RATIO; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STROKE; UNSTABLE ANGINA PECTORIS;

EID: 78650768130     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6273     Document Type: Article

References (48)

1. Morrison HI, Schaubel D, Desmeules M, Wigle DT. Serum folate and risk of fatal coronary heart disease. JAMA 1996;275:1893-6. (Pubitemid 26196449)
2. Rimm EB, Willett WC, Hu FB, Sampson L, Colditz GA, Manson JE, et al. Folate and vitamin B6 fromdiet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359-64. (Pubitemid 28133864)
3. Hu FB, Bronner L, Willett WC, Stampfer MJ, Rexrode KM, Albert CM, et al. Fish and omega-3 fatty acid intake and risk of coronary heart disease in women. JAMA 2002;287:1815-21. (Pubitemid 34303626)
4. Albert CM, Campos H, Stampfer MJ, Ridker PM, Manson JE, Willett WC, et al. Blood levels of long-chain n-3 fatty acids and the risk of sudden death. N Engl J Med 2002;346:1113-8. (Pubitemid 34984601)
5. Erkkilä AT, Lehto S, Pyörälä K, Uusitupa MI. n-3 Fatty acids and 5-y risks of death and cardiovascular disease events in patients with coronary artery disease. Am J Clin Nutr 2003;78:65-71. (Pubitemid 39655249)
6. He K, Merchant A, Rimm EB, Rosner BA, Stampfer MJ, Willett WC, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004;35:169-74.
7. Mc Cully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56:111-28.
8. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease.N Engl J Med 1991;324:1149-55.
9. Boushey CJ, Beresford SA, OmennGS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274:1049-57.
10. Danesh J, Lewington S. Plasma homocysteine and coronary heart disease. J Cardiovasc Res 1988;5:229-32.
11. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002;31:59-70.
12. Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006;333:1114-7. (Pubitemid 44863652)
13. Homocysteine Lowering Trialists' Collaboration. Dose-dependent effects of folic acid on blood concentrations of homocysteine: a meta-analysis of the randomized trials. Am J ClinNutr 2005;82:806-12.
14. B-Vitamin Treatment Trialists' Collaboration. Homocysteine-lowering trials for prevention of cardiovascular events: a review of the design and power of the large randomized trials. Am Heart J 2006;151:282-7.
15. Baker F, Picton D, Blackwood S, Hunt J, Erskine M. Blinded comparison of folic acid and placebo in patients with ischemic heart disease: an outcome trial. Circulation 2002;106 (suppl II):S741.
16. Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 2004;291:565-75.
17. Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A, Steigen T, et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88.
18. The Heart Outcomes Prevention Evaluation (HOPE)2 Investigators. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567-77.
19. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, et al. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease. JAMA 2008;299:2027-36.
20. Jamison RL,Hartigan P, Kaufman JS,Goldfarb DS, Warren SR, Guarino PD, et al. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial. JAMA 2007;298:1163-70.
21. Ebbing M, Bleie Ø, Ueland PM, Nordrehaug JE, Nilsen DW, Vollset SE, et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography. A randomized controlled trial. JAMA 2008;300:795-804.
22. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors. JAMA 2010;24:2485-94.
23. The VITATOPS Trial Study Group. B-vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurology 2010;9:855-65.
24. Kris-Etherton PM, Harris WS, Appel LJ. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation 2002;106:2747-57.
25. Bucher HC, Hengstler P, Schindler C, Meier G. N-3 polyunsaturated fatty acids in coronary heart disease: a meta-analysis of randomized controlled trials. Am J Med 2002;112:298-304. (Pubitemid 34219443)
26. Kromhout D. The inverse relation between fish consumption and 20 years mortality from coronary disease. N Engl JMed 1985;312:1205-9. (Pubitemid 15009153)
27. He K, Song Y, Daviglus ML, Liu K, Van Horn L, Dyer AR, et al. Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies. Circulation 2004;109:2705-11.
28. Wang C, Harris WS, Chung M, Lichtenstein AH, Balk EM, Kupelnick B, et al. N-3 fatty acids from fish or fish-oil supplements, but not alphalinoleic acid, benefit cardiovascular disease outcomes in primary-and secondary-prevention studies: a systematic review. Am J Clin Nutr 2006;84:5-17.
29. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Moore H, Worthington HV, et al. Omega 3 fatty acids for prevention and treatment of cardiovascular disease. Cochrane Database Syst Rev 2004;18:CD003177.
30. Burr ML, Fehily AM, Gilbert JF, Rogers S, Holliday RM, Sweetnam PM, et al. Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989;2:757-61.
31. Gissi-Prevenzione Investigators. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E aftermyocardial infarction: results of the GISSI-Prevenzione Trial. Lancet 1999;354:447-55.
32. Raitt MH, Connor WE, Morris C, Kron J, Halperin B, Chugh SS, et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-91.
33. Brouwer IA, Raitt MH, Dullemeijer C, Kraemer DF, Zock PL, Morris C, et al. Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. Eur Heart J 2009;30:820-6.
34. Burr ML, Ashfield-Watt PA, Dunstan FD, Fehily AM, Breay P, Ashton T, et al. Lack of benefit of dietary advice tomen with angina: results of a controlled trial. Eur J Clin Nutr 2003;57:193-200.
35. Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The SU. FOL.OM3 Study: a secondary prevention trial testing the impact of supplementation with folate and B-vitamins and/or omega-3 PUFA on fatal and non fatal cardiovascular events, design, methods and participants characteristics. Trials 2008;9:1-9.
36. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl JMed 2000;342:145-53.
37. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-22.
38. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplement: meta-analysis of randomised trials. BMJ 1998;316:894-8.
39. Pentieva K, McNulty H, Reichert R, Ward M, Strain J, McKillop D, et al. The short term bioavailabilities of [6S]-5-methyltetrahydrofolate and folic acid are equivalent in men. J Nutr 2004;134:580-5. (Pubitemid 38298499)
40. Schnyder G, Roffi M, Pin R, Roffi M, Flammer Y, Hess OM. Decreased rate of coronary restenosis after lowering of plasma homocysteine levels. N Engl JMed 2001;345:1593-600.
41. Lange H, Suryapranata H, De Luca G, Börner C, Dille J, Kallmayer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81.
42. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, et al. Efficacy of folic acid supplementation in stroke prevention: a meta-analysis. Lancet 2007;369:1876-82.
43. Clarke R, Halsey J, Lewington A, Lonn E, Armitage J, Manson JE, et al. Effects of lowering homocysteine levels with B vitamins on cardiovascukar disease, cancer and cause-specific mortality. Arch Intern Med (forthcoming).
44. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007;369:1090-8.
45. Gissi-HF Investigators, Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1223-30.
46. Kromhout D, Giltay EJ, Geleijnse JM, for the Alpha Omega Trial Group. N-3 fatty acids and cardiovascular events aftermyocardial infarction. N Engl J Med 2010;363:2015-26.
47. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002;105:1897-903.
48. London B, Albert C, Anderson ME, Giles WR, Van Wagoner DR, Balk E, et al. Omega-3 fatty acids and cardiac arrhythmias: prior studies and recommendations for future research: a report from the National Heart, Lung, and Blood Institute and Office of Dietary Supplements Omega-3 Fatty Acids and their Role in Cardiac Arrhythmogenesis Workshop. Circulation 2007;116:320-35.